SA
Shri Ashish Rajanikant Patel Dirigeant
Other
IN IN · SEBI (PIT + SAST)
Discover the complete record of transactions filed by Shri Ashish Rajanikant Patel, Dirigeant. Officer active across 1 companies, notably Lincoln Pharmaceuticals Limited. Cumulatively, 37 disclosures have been published. The latest transaction was filed on 14 June 2022 (Purchase). Regulator: SEBI (PIT + SAST). The full history is openly available.
Declarations 37 total
€140,333 38,000 shares @ €3.693
Equity Shares
SEBI:e1c81ac3db111b7afd8ff207a609ba184123a673 · 14 Jun 2022
Ideal exit: 11 Mar 2023 (T+270) €121,322 33,000 shares @ €3.6764
Equity Shares
SEBI:e33895a2627e055ed161d9a1b5d82c2f4ad87362 · 14 Jun 2022
Ideal exit: 11 Mar 2023 (T+270) €122,214 33,500 shares @ €3.6482
Equity Shares
SEBI:237038c674d856283255d90dfb88fd139a37e151 · 13 Jun 2022
Ideal exit: 10 Mar 2023 (T+270) €121,795 35,000 shares @ €3.4799
Equity Shares
SEBI:a03c66fe8e378d43945dc4a2271d6990f5e158da · 8 Jun 2022
Ideal exit: 5 Mar 2023 (T+270) €120,231 34,500 shares @ €3.4849
Equity Shares
SEBI:6ea75184c774778bacebca49b2cbd8fa4c7ff304 · 9 Jun 2022
Ideal exit: 6 Mar 2023 (T+270) €119,146 34,500 shares @ €3.4535
Equity Shares
SEBI:5d7d93f95b64e054912c48203d0f69d7cc758376 · 6 Jun 2022
Ideal exit: 3 Mar 2023 (T+270) €121,226 35,000 shares @ €3.4636
Equity Shares
SEBI:b49ad25a0a02327b688c988eb87802e9f7678b13 · 7 Jun 2022
Ideal exit: 4 Mar 2023 (T+270) €129,841 40,000 shares @ €3.246
Equity Shares
SEBI:a97b4f6125bee7b019f28d20c8018179704c3a9a · 27 May 2022
Ideal exit: 21 Feb 2023 (T+270) €108,894 35,000 shares @ €3.1113
Equity Shares
SEBI:ddbf256533fe0b9fd0661d322c50c054b6596057 · 26 May 2022
Ideal exit: 20 Feb 2023 (T+270) €70,816 20,000 shares @ €3.5408
Equity Shares
SEBI:1069fb1b783249c9fc4ba7655021ee7562b3de8a · 25 Feb 2022
Ideal exit: 22 Nov 2022 (T+270) €104,204 26,000 shares @ €4.0078
Equity Shares
SEBI:5673855006c8d00de1e5f0b0592fae47ddb5346f · 21 Dec 2021
Ideal exit: 17 Sept 2022 (T+270) €143,672 34,500 shares @ €4.1644
Equity Shares
SEBI:65f1cca4c8e40aed09427544520b3ec86ed66f64 · 16 Dec 2021
Ideal exit: 12 Sept 2022 (T+270) €70,505 16,500 shares @ €4.2731
Equity Shares
SEBI:d1464bb9fe48dc090db9ba259a83146768d5bd52 · 9 Dec 2021
Ideal exit: 5 Sept 2022 (T+270) €146,083 33,500 shares @ €4.3607
Equity Shares
SEBI:bd6f132eb8bca452ac4be6748638343c856214a9 · 9 Dec 2021
Ideal exit: 5 Sept 2022 (T+270) €124,943 30,000 shares @ €4.1648
Equity Shares
SEBI:a47eef291301e3168d466db7aa1fbab6e705d12a · 6 Dec 2021
Ideal exit: 2 Sept 2022 (T+270) €133,234 32,000 shares @ €4.1636
Equity Shares
SEBI:c97474df3f3848ea2d294e8cc4a4f1f3810357cf · 6 Dec 2021
Ideal exit: 2 Sept 2022 (T+270) €96,064 25,000 shares @ €3.8426
Equity Shares
SEBI:a737186c7973a61d1386183b5cdfb4c93b51d674 · 30 Nov 2021
Ideal exit: 27 Aug 2022 (T+270) €40,380 10,500 shares @ €3.8457
Equity Shares
SEBI:dd1c95240f0d0683913dbb11cd6a5f39d2e52387 · 1 Dec 2021
Ideal exit: 28 Aug 2022 (T+270) €96,937 24,000 shares @ €4.0391
Equity Shares
SEBI:f4884b8b73e3dc775dfeffb6615676204c4fd996 · 24 Nov 2021
Ideal exit: 21 Aug 2022 (T+270) €72,924 19,000 shares @ €3.8381
Equity Shares
SEBI:b2d5721dc2dd14160c8fd3bd6957e799be434186 · 22 Nov 2021
Ideal exit: 19 Aug 2022 (T+270) €97,531 25,000 shares @ €3.9013
Equity Shares
SEBI:216ecd0e48da85d56c7322581cec185e6b6c6b93 · 18 Nov 2021
Ideal exit: 15 Aug 2022 (T+270) €135,722 31,000 shares @ €4.3781
Equity Shares
SEBI:ea40bd9e90179ef2c8f1d7243ab74cc1f6072dd6 · 27 Sept 2021
Ideal exit: 24 Jun 2022 (T+270) €154,354 35,000 shares @ €4.4101
Equity Shares
SEBI:b551004bfbcb4902ca3e471c8641cc720b006cf8 · 20 Sept 2021
Ideal exit: 17 Jun 2022 (T+270) €98,040 23,500 shares @ €4.1719
Equity Shares
SEBI:0dd8a558c4ec695a60f00370695ff75858dcf2ee · 8 Sept 2021
Ideal exit: 5 Jun 2022 (T+270) €206,524 50,000 shares @ €4.1305
Equity Shares
SEBI:1f1dc3a7476b73475988b33dbcacb735f09a6100 · 7 Sept 2021
Ideal exit: 4 Jun 2022 (T+270) 25 of 37 declarations
Load more (12 remaining) About Shri Ashish Rajanikant Patel Shri Ashish Rajanikant Patel is an executive at Lincoln Pharmaceuticals Limited. He is involved in managing the company's operations, which specializes in manufacturing pharmaceutical products. His role is essential in ensuring product quality.